CHEMOATTRACTANTS INDUCE RAPID RELEASE OF THE INTERLEUKIN-1 TYPE-II DECOY RECEPTOR IN HUMAN POLYMORPHONUCLEAR CELLS

被引:71
作者
COLOTTA, F
ORLANDO, S
FADLON, EJ
SOZZANI, S
MATTEUCCI, C
MANTOVANI, A
机构
[1] IST RIC FARMACOL MARIO NEGRI,CTR DANIELA & CATULLO BORGOMAINERIO,I-20157 MILAN,ITALY
[2] UNIV BRESCIA,DEPT BIOTECHNOL,GEN PATHOL SECT,BRESCIA,ITALY
关键词
D O I
10.1084/jem.181.6.2181
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Molecules representative of different classes of chemotactic agents, including formyl-Met-Leu-Phe (FMLP), C5a, leukotriene B-4, platelet-activating factor, and interleukin (IL)-8, caused a rapid reduction in the IL-1 binding capacity by human polymorphonuclear leukocytes (PMN), a cell type expressing predominantly the IL-1 type II decoy receptor (IL-1 decoy RII). N-t-Boc-Met-Leu-Phe, an antagonist for the FMLP receptor, inhibited the loss of IL-1 binding capacity induced by FMLP. Monocyte chemotactic protein 1, a chemokine related to IL-8 but inactive on PMN, had no effect on IL-1 binding in this cell type. FMLP was selected for further detailed analysis of chemoattractant-induced loss of IL-1 binding by PMN. The action of FMLP was rapid, reaching 50% of its maximum (80%) at 30 s, the earliest measurable time point, and plateauing between 10 and 30 min. Dose-response analysis revealed that maximal reduction of IL-1 binding was reached at FMLP concentrations that were also optimal for chemotaxis (50% effective dose = 5 x 10(-9) M). The loss of IL-1 binding capacity caused by FMLP was determined by a reduction in receptor number with no change in their affinity. The effect of FMLP on IL-1 receptor (IL-1R) was selective in that the PMN surface structures IL-8R, CD16, CD18, and major histocompatibility complex class I antigens were unaffected under these conditions. Loss of surface IL-1R was not due to an augumented rate of internalization, FMLP caused rapid release of a 45-kD IL-1-binding molecule identified as the IL-1 decoy RII. After FMLP-induced release, PMN reexpressed newly synthesized receptors, reaching basal levels by 4 h. FMLP-induced release of the IL-1 decoy RII did not impair the responsiveness of PMN to IL-1 in terms of promotion of survival and cytokine production. FMLP-induced release of the IL-1 decoy RII was unaffected by protein synthesis inhibitors, was blocked by certain protease inhibitors, and was mimicked by agents (the Ca++ ionophore A23187 and phorbol myristate acetate) that recapitulate elements in the signal transduction pathway of chemoattractant receptors. The time frame and concentration range of chemoattractant-induced rapid release of the IL-1 decoy RII are consistent with the view that IL-1 decoy RII release is an early event in the multistep process of leukocyte recruitment. Rapid chemoattractant-induced IL-1 decoy RII release in the circulation may counteract IL-1 leaking into the systemic circulation from sites of inflammation while preserving the capacity of leukocytes to respond to IL-1 in tissues. This phenomenon may contribute as well to the antiinflammatory effect of systemic administration of chemotactic agents.
引用
收藏
页码:2181 / 2188
页数:8
相关论文
共 23 条
[1]  
BERTANI A, 1989, BLOOD, V74, P1811
[2]   THE TYPE-II DECOY RECEPTOR - A NOVEL REGULATORY PATHWAY FOR INTERLEUKIN-1 [J].
COLOTTA, F ;
DOWER, SK ;
SIMS, JE ;
MANTOVANI, A .
IMMUNOLOGY TODAY, 1994, 15 (12) :562-566
[3]   INTERLEUKIN-1 TYPE-II RECEPTOR - A DECOY TARGET FOR IL-1 THAT IS REGULATED BY IL-4 [J].
COLOTTA, F ;
RE, F ;
MUZIO, M ;
BERTINI, R ;
POLENTARUTTI, N ;
SIRONI, M ;
GIRI, JG ;
DOWER, SK ;
SIMS, JE ;
MANTOVANI, A .
SCIENCE, 1993, 261 (5120) :472-475
[4]  
COLOTTA F, 1994, J BIOL CHEM, V269, P12403
[5]  
DINARELLO CA, 1991, BLOOD, V77, P1627
[6]   IDENTIFICATION OF AN INTERLEUKIN-1 BETA BINDING-PROTEIN IN HUMAN PLASMA [J].
EASTGATE, JA ;
SYMONS, JA ;
DUFF, GW .
FEBS LETTERS, 1990, 260 (02) :213-216
[7]   A 48-WELL MICRO CHEMOTAXIS ASSEMBLY FOR RAPID AND ACCURATE MEASUREMENT OF LEUKOCYTE MIGRATION [J].
FALK, W ;
GOODWIN, RH ;
LEONARD, EJ .
JOURNAL OF IMMUNOLOGICAL METHODS, 1980, 33 (03) :239-247
[8]  
GIRI JG, 1990, J BIOL CHEM, V265, P17416
[9]  
HECHTMAN DH, 1991, J IMMUNOL, V147, P883
[10]  
LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163